期刊文献+

芪苈强心胶囊辅治老年慢性心力衰竭疗效观察 被引量:5

下载PDF
导出
摘要 目的观察芪苈强心胶囊辅治老年慢性心力衰竭的临床疗效。方法将60例老年慢性心力衰竭患者随机分为治疗组和对照组各30例。对照组给予阿司匹林、硝酸酯、β-受体阻滞剂、利尿剂等治疗;治疗组在对照组治疗基础上予芪苈强心胶囊口服,每次4粒,每天3次。2组均3个月为1个疗程。治疗后比较2组临床疗效,心功能、症状改善情况,心血管事件发生情况和不良反应。结果治疗组总有效率为90.0%高于对照组的70.0%,差异有统计学意义(P<0.05)。2组治疗后心肌耗氧量、NYHA分级及LVEF均改善,且治疗组治疗后优于对照组,差异均有统计学意义(P<0.05)。治疗组患者心力衰竭相关临床症状改善情况优于对照组,因心力衰竭至门诊就诊率及再次住院率均低于对照组,差异均有统计学意义(P<0.05)。结论芪苈强心胶囊辅治老年慢性心力衰竭疗效显著,可明显改善患者临床症状及心功能,且不良反应轻微,值得临床推广应用。
出处 《临床合理用药杂志》 2012年第4期63-64,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献5

二级参考文献60

共引文献181

同被引文献72

  • 1XIAO H, SONG Y, LI Y, et al. Qiliqiangxin regu- lates the balance between tumor necrosis factor-a and interleukin-10 and improves cardiac function in rats with myocardial infarction[J]. Cell Immunol, 2009, 260:51-55.
  • 2ZOU Y, LIN L, YE Y, et al. Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice[J]. Cardiovasc Pharmacol, 2012, 59: 268 - 280.
  • 3LIU W, CHEN J, XU T, et al. Qiliqiangxin im- proves cardiac function in spontaneously hypertensive rats through the inhibition of cardiac chymase[J]. Am J Hypertens,2012,25 : 250- 260.
  • 4WEI Y, LIU X, HOU L, et al. Qiliqiangxin affects L type Ca2+ current in the normal and hypertrophied rat heart[J]. Evid Based Complement Ahernat Med, 2012,2012:131830.
  • 5LI X, ZHANG J, HUANG J, et al. A multicenter randomized double-blind parallel-group placebo-con- trolled study of the effects of qili qiangxin capsules in patients with chronic heart failure[J]. J Am Coll Car- diol,2013 : S0735.
  • 6梁国钦,戴兆燕,廖华.不同疗程芪苈强心胶囊治疗慢性充血性心力衰竭患者的安全性评价[J].中国保健营养(中旬刊),2012,6(6):321-322.
  • 7WANG L, ZHOU G B, LIU P, et al. Dissection of mechanisms of Chinese medicinal formula Realgavln digo naturalis as an effective treatment for promyelo- cytic leukemia[J]. Proc Natl Acad Sci USA, 2008, 105:4826-4831.
  • 8ZHANG L, LIU Y, LU X T, et al. Traditional Chi- nese medication Tongxinluo dose-dependently en- hances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy[J]. Am J Physi- ol Heart Circ Physiol, 2009,297 : H2004- 2014.
  • 9LI X D, YANG Y J, GENG Y J, et al. Tongxinluo reduces myocardial no-reflow and ischemia-reperfusion injury by stimulating the phosphorylation of eNOS via the PKA pathway[J]. American journal of physiology[J]. Am J Physiol Heart Circ Physiol, 2010, 299: H1255-1261.
  • 10HU J, LIU Y F, WU C F, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide- based therapy in newly diagnosed acute promyelocytic leukemia[J]. Proc Natl Acad Sci U S A, 2009,106: 3342-3347.

引证文献5

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部